-
急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是发生于淋巴系前体细胞的恶性肿瘤,从免疫表型上可分为急性T淋巴细胞白血病(T-ALL)和急性B淋巴细胞白血病(B-ALL)。白血病相关免疫表型是相关基因表达异常的表观特征之一,对ALL的诊断、治疗后的监测和预后判断上都有极其重要的价值[1-2]。CD304是一种非酪氨酸激酶的跨膜C型凝集素,是血管内皮生长因子共受体,参与神经元引导和血管生成,可在浆细胞样树突细胞、内皮细胞和多种实体瘤上表达,CD304异常表达对诊断母细胞性浆细胞样树突细胞肿瘤具有重要价值[3-4]。目前,CD304在ALL中表达和应用价值国内尚未发现相关文献报道,本研究通过对ALL细胞CD304表达进行分析,并探讨其临床意义。
-
BCR-ABL1阳性病人CD304表达阳性率高于E2A-PBX1和融合基因阴性病人(P < 0.05);CD304阴性和阳性B-ALL病人的性别、年龄、白细胞计数(WBC)、红细胞计数(RBC)、血红蛋白(Hb)和血小板计数(PLT)比较,差异均无统计学意义(P>0.05)(见表 1)。
临床特征 CD304阳性
(n=14)CD304阴性
(n=18)t P 男/女 7/7 11/7 — >0.05* 年龄/岁 36.5±19.5 33.6±19.2 0.42 >0.05 WBC/(×109/L) 25.9±39.9 51.3±84.9 1.12△ >0.05 RBC/(×1012/L) 2.59±1.06 2.33±0.86 0.77 >0.05 Hb /(g/L) 78.1±32.1 69.7±23.6 0.86 >0.05 PLT(×109/L) 27.4±46.3 53.5±52.4 1.47 >0.05 融合基因 BCR-ABL1 10 2 E2A-PBX1 0 3 MLL/AF4 0 2 15.65# < 0.01 TEL-AML1 1 0 阴性 3 11 *示Fisher′s确切概率法; #示χ2值; △示t′值 表 1 B-ALL病人一般临床资料比较(x±s)
-
5例T-ALL细胞和10例对照者B细胞上均不表达CD304,B-ALL病人43.75%(14/32)表达CD304:10例BCR-ABL阳性(12例)、1例TEL-AML1阳性和3例融合基因阴性(14例)病人CD304阳性表达,而3例E2A-PBX1阳性和2例MLL/AF4阳性病人CD304阴性表达。CD304表达模式见图 1。
-
与CD304阴性比较,CD304阳性病人B-ALL细胞CD66c表达频率升高(P < 0.01)(见表 2)。
n CD7 CD33 CD10 CD34 CD9 CD20 CD15 CD13 CD56 CD38 CD66c CD304阳性 14 1 5 13 13 13 5 1 7 7 12 13 CD304阴性 18 — 6 13 11 16 4 2 6 8 18 6 χ2 — 0.02 0.00 1.06 2.71 0.00 0.20 0.00 0.91 1.00 0.85 11.57 P — >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 < 0.01 表 2 CD304阴、阳性表达的B-ALL白血病相关CD阳性频率比较(n)
-
共检测了21份样本MRD,PCR阳性11份,FCM阳性10份,共阳性10份,阳性符合率为91%,阴性符合率91%,总符合率为95%。
急性B淋巴细胞白血病CD304表达的临床意义
The clinical significance of expression of CD304 in B-cell acute lymphoblastic leukemia
-
摘要:
目的探讨急性B淋巴细胞白血病(B-ALL)CD304表达的临床意义及其应用价值。 方法采用流式细胞术(FCM)检测初诊的32例B-ALL细胞CD304和相关白血病抗原表达、5例急性T淋巴细胞白血病(T-ALL)和10例良性血液病对照者细胞CD304的表达; 21份初诊时融合基因和CD304共阳性的治疗后B-ALL样本, FCM和PCR检测微小残留病(MRD)水平, 比较两者符合率。 结果BCR-ABL1阳性病人CD304表达阳性率高于E2A-PBX1和融合基因阴性病人(P < 0.05)。5例T-ALL细胞和10例对照者B细胞上CD304均阴性表达, 初诊43.75%(14/32)B-ALL病人CD304阳性表达: 10例BCR-ABL阳性(12例)、1例TEL-AML1阳性和3例融合基因阴性(14例)病人CD304阳性表达, 而3例E2A-PBX1阳性和2例MLL/AF4阳性病人CD304阴性表达。CD304阳性病人B-ALL细胞CD66c表达频率升高(P < 0.01)。21例MRD中, PCR阳性11份, FCM阳性10份, 共阳性10份, 与PCR结果比较, FCM阳性符合率为91%, 总符合率为95%。 结论CD304在B-ALL中异常表达对诊断和监测MRD具有重要的临床价值。 -
关键词:
- B细胞急性淋巴细胞白血病 /
- CD304 /
- 微小残留病
Abstract:ObjectiveTo investigate the clinical significance and application value of CD304 expression in B-cell acute lymphoblastic leukemia(B-ALL). MethodsThe expression of CD304 in 32 newly diagnosed B-ALL patients, 5 T-cell acute lymphoblastic leukemia patients and 10 control cases with benign hematologic disease were tested by flow cytometry(FCM); 21 specimens in B-ALL patients with co-positive BCR-ABL and CD304 after treatment were detected for minimal residual disease(MRD) by FCM and PCR, and the coincidence rate was then compared. ResultsThe positive rate of CD304 expression in BCR-ABL1 positive patients was higher than those in E2A-PbX1 and fusion gene-negative patients.CD304 were negative expression in T-ALL(n=5) and control groups(n=10).CD304 was positive in 43.75%(14/32) in newly diagnosed B-ALL cases, including 10 positive in 12 BCR-ABL, 1 positive in TEL-AML1, and 3 positive without fusion gene, while CD304 was negative in 3 E2A-PBX and 2 MLL/AF4 cases.The expression frequency of CD66c in CD304-positive B-ALL was increased(P < 0.05).As for MRD of 21 samples, 11 samples were PCR positive, 10 were FCM positive, 10 were double positive.Compared with PCR, the positive coincidence rare of FCM was 91% and total coincidence rare was 95%. ConclusionsCD304 abnormal expressed in B-ALL has an important clinical value in the diagnosis and monitoring MRD. -
Key words:
- B-cell acute lymphoblastic leukemia /
- CD304 /
- minimal residual disease
-
表 1 B-ALL病人一般临床资料比较(x±s)
临床特征 CD304阳性
(n=14)CD304阴性
(n=18)t P 男/女 7/7 11/7 — >0.05* 年龄/岁 36.5±19.5 33.6±19.2 0.42 >0.05 WBC/(×109/L) 25.9±39.9 51.3±84.9 1.12△ >0.05 RBC/(×1012/L) 2.59±1.06 2.33±0.86 0.77 >0.05 Hb /(g/L) 78.1±32.1 69.7±23.6 0.86 >0.05 PLT(×109/L) 27.4±46.3 53.5±52.4 1.47 >0.05 融合基因 BCR-ABL1 10 2 E2A-PBX1 0 3 MLL/AF4 0 2 15.65# < 0.01 TEL-AML1 1 0 阴性 3 11 *示Fisher′s确切概率法; #示χ2值; △示t′值 表 2 CD304阴、阳性表达的B-ALL白血病相关CD阳性频率比较(n)
n CD7 CD33 CD10 CD34 CD9 CD20 CD15 CD13 CD56 CD38 CD66c CD304阳性 14 1 5 13 13 13 5 1 7 7 12 13 CD304阴性 18 — 6 13 11 16 4 2 6 8 18 6 χ2 — 0.02 0.00 1.06 2.71 0.00 0.20 0.00 0.91 1.00 0.85 11.57 P — >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 < 0.01 -
[1] SUI JN, CHEN QS, ZHANG YX, et al. Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance[J]. Am J Hematol, 2019, 94(5): 528. doi: 10.1002/ajh.25431 [2] TSAGARAKIS NJ, PAPADHIMITRIOU SI, PAVLIDIS D, et al. Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia[J]. Int J Lab Hematol, 2019, 41(3): 364. doi: 10.1111/ijlh.12983 [3] SEO HS, HYEON J, SONG IH, et al. Relationship between neuropilin-1 expression and prognosis, according to gastric cancer histology[J]. J Mol Histol, 2020, 51(2): 199. doi: 10.1007/s10735-020-09870-z [4] LYU Z, JIN H, YAN Z, et al. Effects of NRP1 on angiogenesis and vascular maturity inendothelial cells are dependent on the expression of SEMA4D[J]. Int J Mol Med, 2020, 46(4): 1321. [5] 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组. 中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J]. 中华血液学杂志, 2016, 37(10): 837. [6] 时杰, 张茵, 孙恺, 等. CD56和(或)CD117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义[J]. 中华血液学杂志, 2019, 40(8): 693. [7] GUDAPATI P, KHANKA T, CHATTERJEE G, et al. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia[J]. Cytometry B Clin Cytom, 2020, 98(4): 328. doi: 10.1002/cyto.b.21866 [8] SEDEK Ł, THEUNISSEN P, SOBRAL DA COSTA E, et al. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia[J]. J Immunol Methods, 2019, 475: 112429. doi: 10.1016/j.jim.2018.03.005 [9] HATTA Y, HAYAKAWA F, YAMAZAKI E. JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma(ALL/LBL)[J]. Int J Hematol, 2020, 112(4): 439. doi: 10.1007/s12185-020-02965-z [10] GANDEMER V, AUBRY M, ROUSSEL M, et al. CD9 expression can be used to predict childhood TEL/AML1-positive acute lymphoblastic leukemia: proposal for an accelerated diagnostic flowchart. [J]. Leuk Res, 2010, 34(4): 430. doi: 10.1016/j.leukres.2009.09.033 [11] MEYERSON HJ, BLIDARU G, EDINGER A, et al. NRP-1/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia[J]. Am J Clin Pathol, 2012, 137(1): 39. doi: 10.1309/AJCP6VDBL4BRXRQA [12] SOLLY F, ANGELOT F, GARAND R, et al. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry[J]. Cytometry A, 2012, 81(1): 17. [13] TANG GS, WU J, LIU M, et al. BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia[J]. Am J Transl Res, 2015, 7(3): 632. [14] HAGAG AA, NOSAIR NA. Prognostic Impact of Neuropilin-1 Expression in Egyptian Children with B-Lineage Acute Lymphoblastic Leukemia[J]. Mediterr J Hematol Infect Dis, 2015, 7(1): e2015009. [15] SLAYTON WB, SCHULTZ KR, SILVERMAN LB, et al. How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults[J]. Pediatr Blood Cancer, 2020, 11: e28543.